Search results for "Ability"

showing 10 items of 18559 documents

Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer.

2018

// Sonia Molina-Pinelo 1, 2 , Ana Salinas 1 , Nicolas Moreno-Mata 2 , Irene Ferrer 1, 2 , Rocio Suarez 1, 2 , Eduardo Andres-Leon 1 , Manuel Rodriguez-Paredes 4, 5 , Julian Gutekunst 4 , Eloisa Jantus-Lewintre 6, 7 , Carlos Camps 8, 9 , Amancio Carnero 1 , Luis Paz-Ares 1, 2 1 Instituto de Biomedicina de Sevilla (IBIS) (HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain 2 Medical Oncology Department, Hospital Universitario Doce de Octubre & Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spain 3 Thoracic Surgery Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain 4 Division of Epigenetics, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg, Germany…

0301 basic medicineOncologymedicine.medical_specialtyPathology03 medical and health sciences0302 clinical medicineInternal medicineCancer genomeMedicineCOPDIn patienttranscriptional regulationLung cancerGenome stabilityThoracic surgery departmentbusiness.industryDLK1-DIO3 clustermedicine.diseaselung cancer030104 developmental biologyOncologyNormal lung030220 oncology & carcinogenesisDNA methylationbusinessLung tissueepigeneticResearch Paper
researchProduct

Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or…

2016

Background: IMAB362, a chimeric monoclonal antibody that mediates specific killing of cancer cells expressing the tight junction protein Claudin18.2 (CLDN18.2) by activation of immune effector mechanisms, has demonstrated single-agent activity and tolerability in patients ( pts) with heavily pretreated gastric cancer. Methods: Pts with advanced/recurrent gastric and GEJ cancer were centrally evaluated for CLDN18.2 expression by immunohistochemistry (CLAUDETECT® 18.2 Histology Kit). Eligible pts had a CLDN18.2 expression of ≥2+ in ≥40% tumor cells, an ECOG PS of 0–1 and were not eligible for trastuzumab. Pts were randomized 1:1 to first-line EOX (epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2…

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryCancerHematologymedicine.diseaseLoading doseOxaliplatinCapecitabine03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyTolerabilityTrastuzumab030220 oncology & carcinogenesisInternal medicineMedicineAdenocarcinomabusinessEpirubicinmedicine.drugAnnals of Oncology
researchProduct

Pharmacogenomics and the treatment of acute myeloid leukemia.

2016

Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy that is primarily treated with combinations of cytarabine and anthracyclines. Although this scheme remains effective in most of the patients, variability of outcomes in patients has been partly related with their genetic variability. Several pharmacogenetic studies have analyzed the impact of polymorphisms in genes encoding transporters, metabolizers or molecular targets of chemotherapy agents. A systematic review on all eligible studies was carried out in order to estimate the effect of polymorphisms of anthracyclines and cytarabine pathways on efficacy and toxicity of AML treatment. Other emerging gene…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentAntineoplastic AgentsBiologyMalignancy03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGeneticsmedicineSNPHumansGenetic variabilityPharmacologyChemotherapyPolymorphism GeneticMyeloid leukemiamedicine.diseaseLeukemia Myeloid Acute030104 developmental biologyPharmacogenetics030220 oncology & carcinogenesisPharmacogenomicsImmunologyCytarabineMolecular MedicinePharmacogeneticsmedicine.drugPharmacogenomics
researchProduct

Sympathetic, metabolic adaptations, and oxidative stress in autism spectrum disorders: How far from physiology?

2018

Autism spectrum disorders (ASD) is a complex and multifaceted neurobehavioral syndrome with no specific cause still identified, despite the worldwide increasing (prevalence for 1,000 children from 6.7 to 14.6, between 2000 and 2012). Many biological and instrumental markers have been suggested as potential predictive factors for the precocious diagnosis during infancy and/or pediatric age. Many studies reported structural and functional abnormalities in the autonomic system in subjects with ASD. Sleep problems in ASD are a prominent feature, having an impact on the social interaction of the patient. Considering the role of orexins (A and B) in wake-sleep circadian rhythm, we could speculate…

0301 basic medicineOrexin-APhysiologyAutism spectrum disorders (ASD); Heart rate (HR); Heart rate variability (HRV); Orexin-A; Oxidative stress; Physiology; Physiology (medical)Case ReportAutism spectrum disorders (ASD); Heart rate (HR); Heart rate variability (HRV); Orexin-A; Oxidative stressmedicine.disease_causelcsh:PhysiologyHeart rate (HR)03 medical and health sciences0302 clinical medicinePhysiology (medical)Heart ratemental disordersmedicineHeart rate variabilityCircadian rhythmlcsh:QP1-981business.industryPediatric agemedicine.diseaseAutism spectrum disorders (ASD)Pathophysiology030104 developmental biologyOxidative stressAutismOxidative streAutism spectrum disorders (ASD); Heart rate (HR); Heart rate variability (HRV); Orexin-A; Oxidative stress;Skin conductancebusinessNeuroscienceHeart rate variability (HRV)030217 neurology & neurosurgeryOxidative stress
researchProduct

Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague–Dawley Rats But Aflibercept Affects…

2019

Gastrointestinal toxicity is a frequently observed adverse event during cancer treatment with traditional chemotherapeutics. Currently, traditional chemotherapeutics are often combined with targeted biologic agents. These biologics, however, possess a distinct toxicity profile, and they may also exacerbate the adverse effects of traditional chemotherapeutics. In this study, we aimed to characterize the gastrointestinal and metabolic changes after a 2-week treatment period with aflibercept, an antiangiogenic VEGFR decoy, and with erlotinib, a tyrosine-kinase inhibitor. Male rats were treated either with aflibercept or erlotinib for 2 weeks. During the 2-week treatment period, the animals in …

0301 basic medicineOriginal articleCancer ResearchBevacizumabANTITUMOR-ACTIVITYmedicine.medical_treatmentBEVACIZUMAB3122 CancersAdipose tissuePharmacologylcsh:RC254-282TOXICITY03 medical and health sciences0302 clinical medicinemedicineOXIDATIVE STRESSCOMBINATIONAdverse effectAfliberceptChemotherapyIntestinal permeabilitybusiness.industryCHEMOTHERAPYmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMETASTATIC COLORECTAL-CANCER1ST-LINE TREATMENT030104 developmental biologyOncology030220 oncology & carcinogenesisCELLSACIDToxicityErlotinibbusinessmedicine.drug
researchProduct

Optimization of PMAxx pretreatment to distinguish between human norovirus with intact and altered capsids in shellfish and sewage samples

2018

Shellfish contamination by human noroviruses (HuNoVs) is a serious health and economic problem. Recently an ISO procedure based on RT-qPCR for the quantitative detection of HuNoVs in shellfish has been issued, but these procedures cannot discriminate between inactivated and potentially infectious viruses. The aim of the present study was to optimize a pretreatment using PMAxx to better discriminate between intact and heat-treated HuNoVs in shellfish and sewage. To this end, the optimal conditions (30 min incubation with 100 μM of PMAxx and 0.5% of Triton, and double photoactivation) were applied to mussels, oysters and cockles artificially inoculated with thermally-inactivated (99 °C for 5 …

0301 basic medicineOyster030106 microbiologyIntercalating dyesSewageGenome ViralReal-Time Polymerase Chain Reactionmedicine.disease_causeMicrobiologyMicrobiology03 medical and health sciencesCapsidbiology.animalmedicineAnimalsHumansColoring AgentsShellfishShellfish2. Zero hungerInfectivityComplex matrixbiologyViability PCRSewagebusiness.industryNorovirusRT-qPCRGeneral MedicineContamination6. Clean water3. Good health030104 developmental biologyCapsidNorovirusbusinessFood Science
researchProduct

Anticancer properties of 4-thiazolidinone derivatives depend on peroxisome proliferator-activated receptor gamma (PPARγ)

2017

Peroxisome proliferator-activated receptors (PPARs) play an important role in numerous chronic diseases such as diabetes, obesity, atherosclerosis and cancer, and PPAR modulators are among the approved drugs and drug-candidates for their treatment. The aim of this study was to elucidate the involvement of PPARs in the mechanism of cytotoxic and pro-apoptotic action of novel anticancer 4-thiazolidinone derivatives (Les-2194, Les-3377, Les-3640) and approved 4-thiazolidinones (Rosiglitazone, Pioglitazone) towards the human squamous carcinoma (SCC-15) cell line. Experiments with 4-thiazaolidinone derivatives and PPAR-specific siRNA were conducted and PPARα, PPARβ and PPARγ mRNA expression was …

0301 basic medicinePPARsCytotoxicityPeroxisome proliferator-activated receptorAntineoplastic AgentsApoptosisPharmacologySCC-1503 medical and health sciencesStructure-Activity Relationship0302 clinical medicineCell Line TumorDrug DiscoverymedicineGene silencingHumansViability assayRNA MessengerReceptorCell ProliferationPharmacologychemistry.chemical_classificationGene knockdownDose-Response Relationship DrugMolecular StructureThiazolothiopyranesOrganic ChemistryGeneral MedicineSquamous carcinomaPPAR gamma030104 developmental biologychemistryCell cultureThiazolidinone030220 oncology & carcinogenesisThiazolidinesDrug Screening Assays AntitumorRosiglitazonemedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct

Expression, Localization, and Significance of Vascular Permeability/Vascular Endothelial Growth Factor in Nasal Polyps

2005

Background The exact etiologic mechanisms leading to the formation of nasal polyps have remained largely obscure. A key phenomenon of this specific type of chronic inflammatory disease in nasal respiratory mucosa is remarkable edema. Vascular permeability/vascular endothelial growth factor (VPF/VEGF) plays an important role in inducing angiogenesis and modulating capillary permeability. Objective To study the expression and localization of VPF/VEGF as a putative key factor in nasal polyp development. Methods Specimens of nasal polyps (n = 12) were harvested during endonasal sinus surgery in patients with polypous chronic rhinosinusitis. Specimens of healthy nasal respiratory mucosa (n = 12)…

0301 basic medicinePathologymedicine.medical_specialty030102 biochemistry & molecular biologybusiness.industryVascular permeabilityChronic inflammatory diseasemedicine.diseaseVascular endothelial growth factor03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOtorhinolaryngologychemistryotorhinolaryngologic diseasesMedicineNasal polyps030223 otorhinolaryngologybusinessAmerican Journal of Rhinology
researchProduct

Lack of R-Ras Leads to Increased Vascular Permeability in Ischemic Retinopathy

2016

PURPOSE. The role of R-Ras in retinal angiogenesis and vascular permeability was evaluated in an oxygen-induced retinopathy (OIR) model using R-Ras knockout (KO) mice and in human diabetic neovascular membranes. METHODS. Mice deficient for R-Ras and their wild-type (WT) littermates were subjected to 75% oxygen from postnatal day 7 (P7) to P12 and then returned to room air. At P17 retinal vascularization was examined from whole mounts, and retinal vascular permeability was studied using Miles assay. Real-time RT-PCR, Western blotting, and immunohistochemistry were used to assess the expression of R-Ras in retina during development or in the OIR model. The degree of pericyte coverage and vasc…

0301 basic medicinePathologymedicine.medical_specialtyAngiogenesisIschemiaVascular permeabilityRetinaNeovascularization03 medical and health scienceschemistry.chemical_compoundmedicineRetinabusiness.industryretinal ischemiaRetinalKorva- nenä- ja kurkkutaudit silmätaudit - Otorhinolaryngology ophthalmologyDiabetic retinopathymedicine.diseaseeye diseasesdiabetic retinopathy030104 developmental biologymedicine.anatomical_structurechemistrysense organsneovascularizationmedicine.symptombusinessverkkokalvodiabeettinen retinopatiaRetinopathyInvestigative Opthalmology & Visual Science
researchProduct

Adrenal Gland and Gastric Malignant Melanoma without Evidence of Skin Lesion Treated with the Oncolytic Virus Rigvir

2020

Adrenal gland melanoma is an extremely rare diagnosis with less than 20 cases reported. The criteria for diagnosing adrenal gland melanoma include involvement of only one adrenal gland, presence of melanin pigment in the histological examination of the tumor tissue, no primary melanoma tumor in any other organ, and no history of resection of pigmented lesions. However, it is complicated to rule out melanoma of unknown primary origin. Here we report a female patient who at the age of 75 years was admitted to hospital due to suspicion of adrenal and gastric tumor. The largest tumor was found in the adrenal gland, thus leading to the diagnosis of primary adrenal gland melanoma presenting metas…

0301 basic medicinePathologymedicine.medical_specialtyCase ReportDiseaseMetastatic melanomalcsh:RC254-28203 medical and health sciences0302 clinical medicinemedicineOncolytic virotherapyAdrenal glandbusiness.industryMelanomaStomachStandard treatmentlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseAdrenal gland melanomaOncolytic virus030104 developmental biologymedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesisSkin lesionbusinessCase Reports in Oncology
researchProduct